Nurix Therapeutics (NASDAQ:NRIX) Insider Sells $53,513.10 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 3,214 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $16.65, for a total transaction of $53,513.10. Following the completion of the transaction, the insider directly owned 120,399 shares in the company, valued at $2,004,643.35. The trade was a 2.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Gwenn Hansen also recently made the following trade(s):

• On Friday, January 30th, Gwenn Hansen sold 4,895 shares of Nurix Therapeutics stock. The stock was sold at an average price of $16.60, for a total transaction of $81,257.00.

Nurix Therapeutics Price Performance

Shares of NASDAQ:NRIX opened at $16.81 on Friday. The company’s fifty day moving average price is $15.83 and its 200-day moving average price is $16.04. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of -5.32 and a beta of 1.88. Nurix Therapeutics, Inc. has a one year low of $8.19 and a one year high of $22.50.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Wednesday, April 8th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). The company had revenue of $6.25 million during the quarter, compared to the consensus estimate of $14.25 million. Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%. As a group, equities research analysts expect that Nurix Therapeutics, Inc. will post -2.92 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Nurix Therapeutics in a research note on Monday, April 27th. Stifel Nicolaus upped their price objective on shares of Nurix Therapeutics from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. Needham & Company LLC reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Nurix Therapeutics in a research note on Thursday, April 23rd. Piper Sandler upped their price objective on shares of Nurix Therapeutics from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Thursday, January 29th. Finally, Wells Fargo & Company cut their price objective on shares of Nurix Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research note on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.46.

Institutional Investors Weigh In On Nurix Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Larson Financial Group LLC boosted its position in Nurix Therapeutics by 339.0% during the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after buying an additional 1,190 shares during the period. Intesa Sanpaolo Wealth Management purchased a new stake in Nurix Therapeutics during the 4th quarter valued at $31,000. Caitong International Asset Management Co. Ltd purchased a new stake in Nurix Therapeutics during the 4th quarter valued at $33,000. Wexford Capital LP purchased a new stake in Nurix Therapeutics during the 3rd quarter valued at $41,000. Finally, Tower Research Capital LLC TRC boosted its position in Nurix Therapeutics by 118.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock valued at $73,000 after buying an additional 3,475 shares during the period.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.